[{"orgOrder":0,"company":"Indivior","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Drinabant","moa":"CB1","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indivior \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/ National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"Indivior","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Indivior \/ Opiant Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Indivior \/ Opiant Pharmaceuticals"},{"orgOrder":0,"company":"Indivior","sponsor":"Addex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Indivior","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0.33000000000000002,"dosageForm":"Oral","sponsorNew":"Indivior \/ Indivior PLC","highestDevelopmentStatusID":"2","companyTruncated":"Indivior \/ Indivior PLC"},{"orgOrder":0,"company":"Indivior","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Indivior","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Indivior \/ BARDA"},{"orgOrder":0,"company":"Indivior","sponsor":"Aelis Farma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Addex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"INDV-1000","moa":"GABA B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptors","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptors","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Opiant Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Indivior \/ Opiant Pharmaceuticals"},{"orgOrder":0,"company":"Indivior","sponsor":"Aelis Farma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AEF0117","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Indivior \/ Aelis Farma","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Aelis Farma"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Indivior","sponsor":"Addex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA B receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Drinabant","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Indivior \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Indivior \/ Sanofi"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"CB receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.20999999999999999,"dosageForm":"Spray","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Addex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0.34000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.20999999999999999,"dosageForm":"Spray","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"C4X Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"C4X_3256","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Indivior","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Addex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0.34000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Alar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Indivior \/ Alar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Alar Pharmaceuticals"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"INDV-2000","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Aelis Farma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"AEF0117","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Addex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Indivior","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Indivior
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
